<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449592</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-06-4196-MKM-CTIL</org_study_id>
    <nct_id>NCT00449592</nct_id>
  </id_info>
  <brief_title>Oral Zinc Therapy for the Prevention of Mucositis</brief_title>
  <official_title>A Ramdomized Double Blined Placebo Controlled Oral Zinc Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Stem Cell Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Zinc is an intracellular mineral with important enzymatic cofactor activities for cell
      membrane stability, DNA and RNA structure. Zinc deficiency is associated with delayed wound
      healing and immune dysfunction. In patietns with hematological malignancies an inverse
      correlation was found between disease stage and zinc level. Patients undergoing high dose
      chemotherapy for hematologic malignancies are predisposed to develop oral and
      gastrointestinal complications, in particular oral mucositis. These patients may have
      relative zinc deficiency, therefore oral zinc therapy may be benefical in the prevention of
      these complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients candidate for High dose chemotherapy with stem cell support for the diagnosis of
      relapsed/resistant Hodgkins or NHL or MM will be screened for enrollment in the study.

      Patients will be randomized in a 1:1 ratio to therapy with either zincol 1 Tab TID or placebo
      1 Tab TID.

      Therapy will start on the morning before commencing chemotherapy and will continue untill the
      first of either discharge day or day 21.

      Response assesment will include:

        1. Mucositis assesment using NCI-CTC and OMAS scores- to be done eod from baseline and
           untill day 21/discharge day if before day 21

        2. Evaluation of zinc levels in the serum, PBMC and saliva- to be done at baseline, day 6/7
           and day 21/discharge day if before day 21.

        3. Collection of clinical outcome data regarding infectious complications including-
           presence and length of febrile neutropenia,use of antibacterial and antifungal
           medications,
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Mucositis grade</measure>
    <time_frame>day -7 to day +21 or discharge day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of maximal mucositis grade</measure>
    <time_frame>day -7 to day +21 or discharge day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall duration of mucositis</measure>
    <time_frame>day -7 to day +21 or discharge day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of severe neutropenia</measure>
    <time_frame>day -7 to day +21 or discharge day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of febrile neutropenia</measure>
    <time_frame>day -7 to day +21 or discharge day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Mucositis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral zinc therapy, intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zinc</intervention_name>
    <description>Oral Zincol 1 Tab TID from day -6/-7 until discharge</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo 1 Tab TID from day -6/-7 until discharge</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing high dose chemotherapy with stem cell support for relapsed or
             resistant Hodgkins or NHL (treated with BEAM protocol) or MM (treated with high dose
             melphalan).

          -  ECOG performance less than or equal to 2

          -  Adequate renal and hepatic function

        Exclusion Criteria:

          -  Presence of any other active malignancy other than BCC of the skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maya Koren-Michowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center</name>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2007</study_first_submitted>
  <study_first_submitted_qc>March 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2007</study_first_posted>
  <last_update_submitted>October 2, 2008</last_update_submitted>
  <last_update_submitted_qc>October 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Maya Koren-Michovitz</name_title>
    <organization>Sheba Medical Center</organization>
  </responsible_party>
  <keyword>Stem cell transplantation</keyword>
  <keyword>Mucositis</keyword>
  <keyword>Zinc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

